Molecular marker for predicting treatment response in advanced renal cell carcinoma: Does the promise fulfill clinical need?

Current Urology Reports

Volumn 15, Issue 1, 2014, Pages

  Garcia Roig, Michael ^a   Ortiz, Nicolas ^a   Lokeshwar, Vinata ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Metastatic renal cell carcinoma; Prognostic markers; Sorafenib; Sunitinib; Tyrosine kinase inhibitors

Indexed keywords

AXITINIB; BEVACIZUMAB; CARBONATE DEHYDRATASE; CHOLESTEROL; EVEROLIMUS; GELATINASE B; LACTATE DEHYDROGENASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT ALPHA2B INTERFERON; SERUM AMYLOID A; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TUMOR MARKER; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; DRUG DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PYRROLE DERIVATIVE;

ADVANCED CANCER; ARTICLE; ENDOTHELIUM CELL; ERYTHROCYTE SEDIMENTATION RATE; GENETIC MARKER; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY METASTASIS; MORBIDITY; NEPHRECTOMY; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; KIDNEY TUMOR; METABOLISM; PATHOLOGY; REVIEW; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; HUMANS; INDOLES; KIDNEY NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84893031630     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-013-0375-0     Document Type: Article

References (67)

1. Palapattu GS, Kristo B, Rajfer J. Paraneoplastic syndromes in urologic malignancy: the many faces of renal cell carcinoma. Rev Urol. 2002;4:163.
2. Bui MH, Seligson D, Han KR, et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res. 2003;9:802.
3. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, et al. Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol. 2011;12:1143.
4. Farace F, Gross-Goupil M, Tournay E, et al. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors. Br J Cancer. 2011;104:1144.
5. Gruenwald V, Beutel G, Schuch-Jantsch S, et al. Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib. BMC Cancer. 2010;10:695.
6. Rini BI, Jaeger E, Weinberg V, et al. Clinical response to therapy targeted at vascular endothelial growth factor inmetastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006;98:756.
7. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumabrefractory metastatic renal cell carcinoma. J Clin Oncol. 2008;26: 3743.
8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312.
9. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med. 2007;5:32.
10. Pena C, Lathia C, Shan M, et al. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res. 2010;16:4853. In a subset of patients (n=903) enrolled in the Treatment Approaches in Renal Cancer Global Evaluation, the authors evaluated levels of plasma proteins, VEGF, TIMP-1, carbonic anhydrase IX, p21Ras, soluble VEGF receptor 2 and VHL gene mutation to determine responses to Sorafenib treatment. Results showed that VEGF, CAIX, TIMP-1, and Ras p21 have prognostic significance for predicting survival in RCC patients, and of these, TIMP-1 has independent prognostic significance.
11. Porta C, Paglino C, De Amici M, et al. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinaseassociated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int. 2010;77:809.
12. Vermaat JS, Gerritse FL, van der Veldt AA, et al. Validation of serum amyloid alpha as an independent biomarker for progressionfree and overall survival in metastatic renal cell cancer patients. Eur Urol. 2012;62:685.
13. Perrin C, Patard JJ, Jouan F, et al. The neutrophil gelatinaseassociated lipocalin, or LCN 2, marker of aggressiveness in clear cell renal cell carcinoma. Prog Urol. 2011;21:851.
14. Zhang HL, Zhu Y, Wang CF, et al. Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib. Int J Urol. 2011;18:422.
15. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13:827.
16. Zurita AJ, Jonasch E,Wang X, et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol. 2012;23:46.
17. Armstrong AJ, George DJ, Halabi S. Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin. J Clin Oncol. 2012;30:3402.
18. Lee CK, Marschner IC, Simes RJ, et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin Cancer Res. 2012;18:3188.
19. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer. 1997;80:1198.
20. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408.
21. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182:1271.
22. Ljungberg B, Cowan NC, Hanbury DC, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol. 2010;58:398. The article contains guidelines and updated recommendations for the diagnosis, treatment, and follow-up of individual patients, in order to improve clinical management of renal cell carcinoma.
23. Chi A, Shirodkar SP, Escudero DO, et al. Molecular characterization of kidney cancer. Cancer. 2012;118:2394.
24. Gahan JC, Gosalbez M, Yates T, et al. Chemokine and chemokine receptor expression in kidney tumors: molecular profiling of histological subtypes and association with metastasis. J Urol. 2012;187:827.
25. Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071.
26. Rini BI, Campbell SC. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol. 2007;177:1978.
27. Mues AC, Haramis G, Rothberg MB, et al. Contemporary experience with laparoscopic radical nephrectomy. J Laparoendosc Adv Surg Tech A. 2011;21:15.
28. Hellenthal NJ, Underwood W, Penetrante R, et al. Prospective clinical trial of preoperative sunitinib in patients with renal cell carcinoma. J Urol. 2010;184:859. In a single institution, prospective clinical trial for patients with localized or metastatic, clearcell, renal cell carcinoma, neoadjuvant treatment with Sunitinib was shown to decrease the size of the primary tumor and was welltolerated.
29. Gorin MA, Ekwenna O, Soloway MS, et al. Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephronsparing surgery. Urology. 2012;79:e11.
30. Kanzaki R, HigashiyamaM, Fujiwara A, et al. Long-term results of surgical resection for pulmonary metastasis from renal cell carcinoma: a 25-year single-institution experience. Eur J Cardiothorac Surg. 2011;39:167.
31. Meimarakis G, Angele M, Staehler M, et al. Evaluation of a new prognostic score (Munich score) to predict long-term survival after resection of pulmonary renal cell carcinoma metastases. AmJ Surg. 2011;202:158.
32. Murthy SC, Kim K, Rice TW, et al. Can we predict long-term survival after pulmonary metastasectomy for renal cell carcinoma? Ann Thorac Surg. 2005;79:996.
33. Pfannschmidt J, Hoffmann H,Muley T, et al. Prognostic factors for survival after pulmonary resection of metastatic renal cell carcinoma. Ann Thorac Surg. 2002;74:1653.
34. Russo P, O'Brien MF. Surgical intervention in patients with metastatic renal cancer:metastasectomy and cytoreductive nephrectomy. Urol Clin North Am. 2008;35:679.
35. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med. 1998;338:1272.
36. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994;7:85.
37. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxiainducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22:7004.
38. Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884.
39. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA J Am Med Assoc. 2006;295:2516.
40. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356: 115.
41. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an antivascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57: 4593.
42. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther. 2006;28:1779.
43. Bukowski RM, Kabbinavar FF, Figlin RA, et al. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol. 2007;25:4536.
44. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103.
45. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427.
46. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228. This article summarizes the changes in RECIST criteria that were originally published in the year 2000. The major change in the criteria is that the number of lesions required to assess tumor burden for response determination was reduced from a maximum of 10 to a maximum of five total (and from five to two per organ, maximum). Assessment of pathological lymph nodes was also included. In addition, the definition of disease progression was classified further.
47. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer. 2012;106:1100.
48. Patard JJ, Fergelot P, Karakiewicz PI, et al. Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer. 2008;123:395.
49. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60:7075.
50. Sandlund J, Oosterwijk E, Grankvist K, et al. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int. 2007;100:556.
51. Phuoc NB, Ehara H, Gotoh T, et al. Prognostic value of the coexpression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma. Oncol Rep. 2008;20:525.
52. Zhou GX, Ireland J, Rayman P, et al. Quantification of carbonic anhydrase IX expression in serum and tissue of renal cell carcinoma patients using enzyme-linked immunosorbent assay: prognostic and diagnostic potentials. Urology. 2010;75:257.
53. Choueiri TK, Vaziri SA, Jaeger E, et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 2008;180:860.
54. Cusatis G, Gregorc V, Li J, et al. Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006;98:1739.
55. Wang WP, Wang KN, Gao Q, et al. Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction. World J Surg Oncol. 2012;10:14.
56. Boos CJ, Lip GY, Blann AD. Circulating endothelial cells in cardiovascular disease. J Am Coll Cardiol. 2006;48:1538.
57. WuH, ChenH,Hu PC. Circulating endothelial cells and endothelial progenitors as surrogate biomarkers in vascular dysfunction. Clin Lab. 2007;53:285.
58. Bhatt RS, Zurita AJ, O'Neill A, et al. Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. Br J Cancer. 2011;105:112.
59. Namdarian B, Tan KV, Fankhauser MJ, et al. Circulating endothelial cells and progenitors: potential biomarkers of renal cell carcinoma. BJU Int. 2010;106:1081.
60. Motzer RJ, Bacik J,Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002;20:289.
61. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649.
62. Vermaat JS, van der Tweel I,Mehra N, et al. Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. Ann Oncol. 2010;21:1472.
63. Sengupta S, Lohse CM, Cheville JC, et al. The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma. Cancer. 2006;106:304.
64. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737.
65. Perez-Gracia JL, Prior C, Guillen-Grima F, et al. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer. 2009;101:1876.
66. Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21:1232.
67. von Eyben FE. A systematic review of lactate dehydrogenase isoenzyme 1 and germ cell tumors. Clin Biochem. 2001;34:441.